Jackson Center, PA, December 23, 2020 – Halberd Corp. (OTC PINK: “HALB“) research has produced a second monoclonal antibody (mAb) against the Covid-19 spike protein.  Initial testing displays a stronger affinity for the SARS-CoV-2 antigen than Halberd’s initial antibody.  Testing continues through the holidays on each antibody to establish potency and specificity (i.e., targets only the SARS-CoV-2 antigen) as well as a potential “cocktail mix” of both antibodies acting in concert.

Halberd’s Chief Technical Officer, Dr. Patricio Reyes, stated, “This is very promising.  In our in vitro experiments, our unique antibodies demonstrated a high degree of affinity and lysis for infected cells.  In vivo studies are getting under way to demonstrate their efficacy in diagnosing COVID-19 as well as preventing viral replication and multi-organ system damage associated with COVID-19.”

William A. Hartman, Chairman, President & CEO, stated, “We believe having multiple antibodies available not only increases our product application options, but also their effectiveness, when used in combination. Mathematically speaking, if each is 90% effective independently, then, absent any interrelationship of the two applications, the combination should be 99% effective.  In other words, the prospect of obtaining diagnostic test false positives or false negatives is substantially reduced when antibodies work in tandem.  The same would be true with regard to the use of antibodies in combination as a therapeutic tool as well as their use as a prophylactic measure in a nasal spray.”

The details of the Halberd-ASU research contract can be viewed here.

If you would like to be added to our email subscriber list, click here and submit the form.

For more information please contact:
William A. Hartman
w.hartman@halberdcorporation.com
support@halberdcorporation.com
www.halberdcorporation.com
Twitter:@HalberdC

About Halberd Corporation.
Halberd Corporation. (OTC-PINK:HALB), is a publicly traded company on the OTC Market, and is in full compliance with OTC Market reporting requirements.  Halberd’s Articles of Incorporation prohibit the company from issuance of convertible debt which would result in dilution. See the company’s Articles of Incorporation here.

The company holds the exclusive rights to the COVID-19 extracorporeal treatment technology provisional patent applications: “Method for Treating and Curing Covid-19 Infection;” “Method for Treating COVID-19 Inflammatory Cytokine Storm for the Reduction of Morbidity and Mortality in COVID-19 Patients;” “Method for Treating and Curing COVID-19 Infection by Utilizing a Laser to Eradicate the Virus,” and, “Nasal Spray To Prevent The Transmission Of Covid-19 Between Humans,” “Nasal Spray to Prevent the Transmission of Covid-19,” and “Method For Treating And Curing Covid-19 Infection By Utilizing Radiofrequency Extracorporeally To Eradicate The Virus.”  Halberd also holds the exclusive rights to the underlying granted U.S. Patent 9,216,386 and U.S. Patent 8,758,287.

Safe Harbor Notice
Certain statements contained herein are “forward-looking statements” (as defined in the Private Securities Litigation Reform Act of 1995). The Companies caution that statements, and assumptions made in this news release constitute forward-looking statements and makes no guarantee of future performance.  Forward-looking statements are based on estimates and opinions of management at the time statements are made.  These statements may address issues that involve significant risks, uncertainties, estimates made by management.  Actual results could differ materially from current projections or implied results. The Companies undertake no obligation to revise these statements following the date of this news release.

 

Investor caution/added risk for investors in companies claiming involvement in COVID-19 initiatives –
On April 8, 2020, SEC Chairman Jay Clayton and William Hinman, the Director of the Division of Corporation Finance, issued a joint public statement on the importance of disclosure during the COVID-19 crisis.

The SEC and Self-Regulatory Organizations are targeting public companies that claim to have products, treatment or other strategies with regard to COVID-19.

The ultimate impact of the COVID-19 pandemic on the Company’s operations is unknown and will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration of the COVID-19 outbreak. Additionally, new information may emerge concerning the severity of the COVID-19 pandemic, and any additional preventative and protective actions that governments, or the Company, may direct, which may result in an extended period of continued business disruption, reduced customer traffic and reduced operations. Any resulting financial impact cannot be reasonably estimated at this time.

We further caution investors that our primary focus and goal is to battle this pandemic for the good of the world. As such, it is possible that we may find it necessary to make disclosures which are consistent with that goal, but which may be adverse to the pecuniary interests of the Company and of its shareholders.